Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Clin Cancer Res. 2017 Mar 24;23(15):4493–4500. doi: 10.1158/1078-0432.CCR-16-2845

Figure 2. RPS predicts residual cancer burden following neoadjuvant chemotherapy in breast cancer.

Figure 2

RCB-0/I=pathologic complete response (pCR)/minimal residual disease; RCB-II/III=moderate/extensive residual disease. Low, intermediate and high RPS values denote the lowest 25th, middle 50th, and highest 25th RPS percentiles. P-values were determined using Chi-Square tests between groups.